Evidence supporting the use of: Bifidobacterium breve
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium breve is a probiotic bacterium that has been investigated for its potential role in supporting gut health, including in inflammatory bowel diseases (IBD) such as Crohn's Disease. The rationale for its use is grounded in the understanding that dysbiosis (an imbalance of the gut microbiota) is a contributing factor to Crohn's Disease, and probiotics may help restore microbial balance, modulate immune responses, and reduce inflammation. Several small clinical trials and preclinical studies have explored the effects of B. breve, alone or in combination with other probiotic strains, on IBD. For example, animal studies have shown that B. breve can reduce colonic inflammation and improve gut barrier function. Some human trials in IBD (more often in ulcerative colitis than Crohn's specifically) have suggested modest benefits in reducing disease activity or maintaining remission, though results have been mixed and sample sizes are often small. Meta-analyses and systematic reviews generally conclude that while certain probiotics may provide benefit in ulcerative colitis, evidence for Crohn's Disease is weaker and less consistent. B. breve is not widely recommended as a standalone therapy for Crohn's Disease in clinical guidelines, but its inclusion in some multi-strain probiotic formulations has been studied. Overall, the scientific evidence supporting B. breve for Crohn's Disease is limited and not definitive, warranting a cautious approach and further research.

More about bifidobacterium breve
More about Crohn's Disease